Navigation Links
Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
Date:3/11/2008

s the gastric pH and thus protects omeprazole from acid degradation.

Important Safety Information about ZEGERID

The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

ZEGERID contains sodium bicarbonate. This should be taken into consideration for patients on a sodium-restricted diet.

ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the future regulatory approval and potential for ZEGERID. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
2. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
3. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
4. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
5. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
6. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
7. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
8. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
9. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
10. Schering-Plough Completes Acquisition of Organon BioSciences
11. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... August 26, 2015 , ... ... that a second US laboratory is to open in Manhattan, Kansas in early ... partnership and long-term growth of research and development through collaboration with researchers from ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. recently installed ... company has added a AS16 Sharples centrifuge to harvest products after fermentation. The ... fungal fermentation process development. , The new centrifuge greatly expands production capabilities ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... CHICAGO, March 9, 2011 GlobalCare Clinical Trials, ... America. GlobalCare provides selected clinical study visits at ... or alternate settings – for study patients to ... therapeutic areas, genomics and personalized medicine in all ...
... BEIJING, March 9, 2011 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc. (Nasdaq: ... agricultural nutrient company in China, today announced that the Company ... on Tuesday, March 15, 2011, to discuss its fourth quarter ... in the live conference call, please dial the following number ...
... March 9, 2011 AccessClosure, Inc., the U.S. ... today results from the first published study* (Journal ... deployment of different vascular closure devices (VCD) as ... trial compared the discomfort associated with the Mynx ...
Cached Biology Technology:GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 2GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 4Yongye International Announces Conference Call to Discuss Fourth Quarter and Full Year 2010 Results 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 3
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... with optics for processing data in computers is coming ... properties of fast and slow light. The long term ... densities by several orders of magnitude and take the ... improved performance with dramatically lower energy consumption. , The ...
... first experiment involving a natural environment, scientists at ... significantly enhances an ecosystem,s productivity. The finding underscores ... dioxide, a main contributor to global warming. ... and the Sloan Lindeman Professor of Biology at ...
... Centre for Addiction and Mental Health (CAMH) has ... mental retardation (MR) along with the eye defect ... unidentified gene that causes this disorder, CC2D2A. ... and biological processes involved in brain development, and ...
Cached Biology News:European light research opens door for optical storage and computing 2Brown scientists say biodiversity is crucial to ecosystem productivity 2New gene discovered for new form of intellectual disability 2
...
... reagents and supplies, for 10 chips, ... to perform high-sensitivity RNA analysis (picogram ... Experion automated electrophoresis system. Supplied are ... RNA HighSens stain, 20 microliters RNA ...
... 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide White solid. PROTECT FROM ... cell-permeable sulfanamido-benzbromarone compound that acts as ... inhibitor of PTP1B (IC 50 ... for PTP1B 403 and PTP1B ...
...
Biology Products: